You are using an outdated browser. Please upgrade your browser to improve your experience and security.

A Strong
Start
For Superior
Survival1,2

5-Year OS Data
Available

VYXEOS demonstrated significantly longer overall survival in patients with sAML compared to traditional chemotherapya, while providing1,2:

  • Higher complete remission rates
  • Improved opportunity for transplant

Median overall survival (primary analysis) of 9.6 months with VYXEOS vs 5.9 months with 7+3, reducing the risk of death by 31% (HR=0.69 [95% CI: 0.52, 0.90], P=0.005b)1. Rate of CR was 38% (n=58/153) with VYXEOS vs 26% (n=41/156) with 7+3; rate of CR+CRi was 48% (n=73/153) with VYXEOS vs 33% (n=52/156) with 7+3.1,2 Overall rate of HSCTc was 35% (n=53/153) for VYXEOS vs 25% (n=39/156) for 7+3.3,d

In a Phase 3, randomized, multicenter, open-label, active-controlled superiority study of VYXEOS vs 7+3 (cytarabine and daunorubicin) in 309 patients (aged 60-75) with newly-diagnosed t-AML or AML-MRC1 See full study design

See VYXEOS long-term
estimated survival data

VYXEOS LONG-TERM OS DATA

Overall survival is more than double at 5 years with VYXEOS (18%) vs 7+3 (8%) based on KM estimates1,3

View data

National Comprehensive Cancer Network® (NCCN®) recommendations

Liposomal daunorubicin and cytarabine (VYXEOS) is the ONLY treatment recommended in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for induction in patients ≥60 years of age with therapy-related AML or antecedent MDS/CMML or AML-MRC (Category 1)4,e,f

Learn more

Outpatient
Possibility

Inpatient and outpatient administration options for appropriate patients

JazzCares

VYXEOS financial assistance and coverage

Group purchasing organization

VYXEOS is now partnering with certain group purchasing organizations

INDICATION

VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.